AZN vs IMNM
AZN: AstraZeneca is a major global biopharmaceutical company dedicated to delivering life-changing medicines across oncology, rare diseases, and diverse chronic conditions. IMNM: Immunome is a clinical-stage biotechnology company leveraging a proprietary platform to discover and develop novel, targeted oncology therapeutics.
Side-by-side fundamentals
| Metric | AZN | IMNM | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $165.98 | $28.52 | |
| Market cap as of 2026-08-24 | $181.5B | $3.2B | |
| P/E as of 2026-08-24 | 23.44 | n/a | |
| PEG as of 2026-08-24 | 2.64 | n/a | |
| Net margin as of 2026-08-24 | +17.0% | -1687.1% | AZN higher |
| Gross margin as of 2026-08-24 | +81.3% | n/a | |
| Operating margin as of 2026-08-24 | +22.8% | -1784.1% | AZN higher |
| ROE as of 2026-08-24 | +21.7% | -51.1% | AZN higher |
| ROA as of 2026-08-24 | +9.1% | -47.3% | AZN higher |
| Debt / equity as of 2026-08-24 | 0.64 | 0.00 | IMNM lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.6% | -63.3% | AZN higher |
| Revenue CAGR (3y) SEC XBRL | +9.8% | -29.6% | AZN higher |
| Dividend yield as of 2026-08-24 | +2.3% | n/a | |
| Beta as of 2026-08-24 | 1.39 | 2.54 | |
| 1-year return as of 2026-08-21 close | +3.1% | +186.6% | IMNM higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.